| Serial Number | 79392996 |
| Word Mark | BDC |
| Filing Date | Tuesday, December 19, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, February 11, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 11, 2025 |
| Goods and Services | Pharmaceutical preparations for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the treatment of cancer; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical preparations for use in preventing and treating infections; pharmaceutical products and preparations for the treatment of respiratory disease; pharmaceutical preparations for the treatment and prevention of cardiovascular disease; pharmaceutical preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical preparations for use in medical diagnostics and imaging; pharmaceutical preparations for the treatment and prevention of renal disease; pharmaceutical preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical preparations for the treatment and prevention of muscular skeletal disease |
| Goods and Services | Scientific and technological services and research and design relating thereto, namely, scientific research and new product design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; medical research services, namely, industrial analysis and research services in the field of medicine; research and development services in the field of pharmaceutical preparations; medical research services; pharmaceutical research services, namely, pharmaceutical testing and clinical trials; scientific research in the nature of conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; scientific research consulting, namely, providing information consultancy and advisory services relating to the aforesaid in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 12, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 12, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Bicycletx Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Bicycletx Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, April 4, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, July 1, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, July 30, 2024 | REFUSAL PROCESSED BY MPU |
| Tuesday, July 30, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, August 17, 2024 | REFUSAL PROCESSED BY IB |
| Friday, April 12, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, April 18, 2024 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, July 2, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, July 3, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, December 16, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, December 16, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, January 21, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, January 21, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, January 21, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, January 23, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 5, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 11, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 11, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Monday, December 16, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 21, 2025 | EXAMINERS AMENDMENT E-MAILED |